Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine Debulking Followed by Obinutuzumab + Ibrutinib Then Maintenance in CLL
DRKS00007710Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Jun 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, obinutuzumab and ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University of Cologne. Started Jun 2015; status: completed.
02
Drugs
bendamustineobinutuzumabibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on DRKS00007710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00007710.